Vigilant Biosciences

About:

Vigilant Biosciences is a innovator and developer of solutions that aid in the early detection and intervention of cancer.

Website: http://vigilantbiosciences.com

Top Investors: National Institutes of Health, venVelo, Florida Institute for the Commercialization of Florida Technology, National Institute of Dental and Craniofacial Research (NIDCR), White Owl Capital Partners

Description:

Vigilant Biosciences is an innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert Oral Cancer and OncAlert Labs product lines include point-of-care and lab-based products that are simple, accurate, and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating, and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016.